Roche’s GA101 Met Goals in Stage One of Trial to Replace Rituxan

Roche Holding AG said a next-generation blood cancer drug met its target in the first stage of a trial that could help the treatment replace top-seller Rituxan in patients with chronic lymphocytic leukemia.
Bloomberg